uniQure (QURE) Competitors $17.00 -0.38 (-2.19%) As of 12:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QURE vs. MLTX, APLS, TLX, SRRK, ARWR, VKTX, AMRX, XENE, KYMR, and CRNXShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include MoonLake Immunotherapeutics (MLTX), Apellis Pharmaceuticals (APLS), Telix Pharmaceuticals (TLX), Scholar Rock (SRRK), Arrowhead Pharmaceuticals (ARWR), Viking Therapeutics (VKTX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Kymera Therapeutics (KYMR), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. uniQure vs. Its Competitors MoonLake Immunotherapeutics Apellis Pharmaceuticals Telix Pharmaceuticals Scholar Rock Arrowhead Pharmaceuticals Viking Therapeutics Amneal Pharmaceuticals Xenon Pharmaceuticals Kymera Therapeutics Crinetics Pharmaceuticals MoonLake Immunotherapeutics (NASDAQ:MLTX) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings. Which has stronger earnings & valuation, MLTX or QURE? MoonLake Immunotherapeutics has higher earnings, but lower revenue than uniQure. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.78-20.61uniQure$27.12M34.39-$239.56M-$3.92-4.34 Does the media refer more to MLTX or QURE? In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than uniQure. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 2 mentions for uniQure. MoonLake Immunotherapeutics' average media sentiment score of 1.30 beat uniQure's score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in MLTX or QURE? 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 4.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend MLTX or QURE? MoonLake Immunotherapeutics currently has a consensus target price of $74.43, indicating a potential upside of 29.93%. uniQure has a consensus target price of $37.45, indicating a potential upside of 120.32%. Given uniQure's stronger consensus rating and higher probable upside, analysts clearly believe uniQure is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78uniQure 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is MLTX or QURE more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,387.98%. MoonLake Immunotherapeutics' return on equity of -40.98% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -40.98% -35.81% uniQure -1,387.98%-1,010.74%-33.27% Which has more volatility and risk, MLTX or QURE? MoonLake Immunotherapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. SummaryMoonLake Immunotherapeutics beats uniQure on 9 of the 15 factors compared between the two stocks. Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$933.12M$3.10B$5.76B$9.85BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-4.3420.9382.4826.51Price / Sales34.39367.07500.41161.56Price / CashN/A43.5325.7028.92Price / Book-242.868.0510.816.51Net Income-$239.56M-$53.35M$3.28B$266.22M7 Day Performance4.55%-0.93%-0.43%-1.21%1 Month Performance23.46%5.97%6.47%3.32%1 Year Performance214.23%10.33%49.57%23.49% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure1.9293 of 5 stars$17.00-2.2%$37.45+120.3%+212.0%$933.12M$27.12M-4.34500MLTXMoonLake Immunotherapeutics2.4612 of 5 stars$55.75+1.7%$74.43+33.5%+28.5%$3.58BN/A-20.052News CoveragePositive NewsAnalyst RevisionAPLSApellis Pharmaceuticals4.3009 of 5 stars$27.57-1.7%$34.12+23.7%-28.4%$3.48B$781.37M-15.15770News CoveragePositive NewsTLXTelix PharmaceuticalsN/A$9.55-5.9%$22.33+133.9%N/A$3.23B$516.72M0.00N/AAnalyst RevisionGap DownHigh Trading VolumeSRRKScholar Rock4.6125 of 5 stars$32.65-1.9%$45.75+40.1%+277.8%$3.14BN/A-11.22140News CoveragePositive NewsARWRArrowhead Pharmaceuticals4.2066 of 5 stars$22.03-1.4%$43.14+95.8%+21.3%$3.05B$3.55M-17.21400News CoverageAnalyst ForecastVKTXViking Therapeutics4.2674 of 5 stars$27.05-1.9%$86.92+221.3%-54.1%$3.04BN/A-17.6820Positive NewsAnalyst RevisionAMRXAmneal Pharmaceuticals3.0479 of 5 stars$9.56+0.1%$11.60+21.3%+12.4%$3.00B$2.79B956.967,600Positive NewsXENEXenon Pharmaceuticals2.6945 of 5 stars$38.71+0.3%$53.20+37.4%-3.3%$2.98B$9.43M-10.90210News CoveragePositive NewsAnalyst ForecastOptions VolumeKYMRKymera Therapeutics3.4748 of 5 stars$41.20-1.3%$58.76+42.6%-6.5%$2.95B$44.71M-11.87170News CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.7992 of 5 stars$30.99+1.1%$68.86+122.2%-33.4%$2.92B$1.39M-7.54210News CoveragePositive News Related Companies and Tools Related Companies MLTX Alternatives APLS Alternatives TLX Alternatives SRRK Alternatives ARWR Alternatives VKTX Alternatives AMRX Alternatives XENE Alternatives KYMR Alternatives CRNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QURE) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QURE Stock Alerts